Cargando…

In-vivo dosimetric analysis in total skin electron beam therapy

BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIALS AND METHODS: Retrospectively collected data on 85...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsayad, Khaled, Moustakis, Christos, Simonsen, Manuela, Bäcker, Dagmar, Haverkamp, Uwe, Eich, Hans Theodor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807580/
https://www.ncbi.nlm.nih.gov/pubmed/33458390
http://dx.doi.org/10.1016/j.phro.2018.05.002
_version_ 1783636771444097024
author Elsayad, Khaled
Moustakis, Christos
Simonsen, Manuela
Bäcker, Dagmar
Haverkamp, Uwe
Eich, Hans Theodor
author_facet Elsayad, Khaled
Moustakis, Christos
Simonsen, Manuela
Bäcker, Dagmar
Haverkamp, Uwe
Eich, Hans Theodor
author_sort Elsayad, Khaled
collection PubMed
description BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIALS AND METHODS: Retrospectively collected data on 85 patients with cutaneous lymphoma or leukemia underwent TSEBT were reviewed. Patients were irradiated on two linear accelerators, in one of two positions (standing, n = 77; reclined, n = 8) and 1830 in vivo TLD measurements were obtained for various locations on 76 patients. RESULTS: The TLD results showed that the two TSEBT techniques were dosimetrically heterogeneous. At several sites, the dose administered correlated with height, weight, and gender. After the first TLD measurement, fourteen patients (18%) required MU modification, with a mean 10% reduction (range, −25 to +35). Individual TLD results allowed us to customize the boost treatment for each patient. For patients who were evaluated in the standing position, the most common underdosed sites were the axilla, perineum/perianal folds, and soles (each receiving 69%, 20%, and 34% of the prescribed dose, respectively). For patients evaluated in a reclining position, surface dose distribution was more heterogeneous. The sites underdosed most commonly were the axilla and perineum/perianal folds (receiving less than one third of prescribed dose). Significant variables were detected with model building. CONCLUSION: TLD measurements were integral to quality assurance for TSEBT. Dose distribution at several anatomical sites correlated significantly with gender, height, and weight of the treated individual and might be predicted.
format Online
Article
Text
id pubmed-7807580
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78075802021-01-14 In-vivo dosimetric analysis in total skin electron beam therapy Elsayad, Khaled Moustakis, Christos Simonsen, Manuela Bäcker, Dagmar Haverkamp, Uwe Eich, Hans Theodor Phys Imaging Radiat Oncol Original Research Article BACKGROUND AND PURPOSE: Thermoluminescent dosimetry (TLD) is an important element of total skin electron beam therapy (TSEBT). In this study, we compare radiation dose distributions to provide data for dose variation across anatomic sites. MATERIALS AND METHODS: Retrospectively collected data on 85 patients with cutaneous lymphoma or leukemia underwent TSEBT were reviewed. Patients were irradiated on two linear accelerators, in one of two positions (standing, n = 77; reclined, n = 8) and 1830 in vivo TLD measurements were obtained for various locations on 76 patients. RESULTS: The TLD results showed that the two TSEBT techniques were dosimetrically heterogeneous. At several sites, the dose administered correlated with height, weight, and gender. After the first TLD measurement, fourteen patients (18%) required MU modification, with a mean 10% reduction (range, −25 to +35). Individual TLD results allowed us to customize the boost treatment for each patient. For patients who were evaluated in the standing position, the most common underdosed sites were the axilla, perineum/perianal folds, and soles (each receiving 69%, 20%, and 34% of the prescribed dose, respectively). For patients evaluated in a reclining position, surface dose distribution was more heterogeneous. The sites underdosed most commonly were the axilla and perineum/perianal folds (receiving less than one third of prescribed dose). Significant variables were detected with model building. CONCLUSION: TLD measurements were integral to quality assurance for TSEBT. Dose distribution at several anatomical sites correlated significantly with gender, height, and weight of the treated individual and might be predicted. Elsevier 2018-05-19 /pmc/articles/PMC7807580/ /pubmed/33458390 http://dx.doi.org/10.1016/j.phro.2018.05.002 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Elsayad, Khaled
Moustakis, Christos
Simonsen, Manuela
Bäcker, Dagmar
Haverkamp, Uwe
Eich, Hans Theodor
In-vivo dosimetric analysis in total skin electron beam therapy
title In-vivo dosimetric analysis in total skin electron beam therapy
title_full In-vivo dosimetric analysis in total skin electron beam therapy
title_fullStr In-vivo dosimetric analysis in total skin electron beam therapy
title_full_unstemmed In-vivo dosimetric analysis in total skin electron beam therapy
title_short In-vivo dosimetric analysis in total skin electron beam therapy
title_sort in-vivo dosimetric analysis in total skin electron beam therapy
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807580/
https://www.ncbi.nlm.nih.gov/pubmed/33458390
http://dx.doi.org/10.1016/j.phro.2018.05.002
work_keys_str_mv AT elsayadkhaled invivodosimetricanalysisintotalskinelectronbeamtherapy
AT moustakischristos invivodosimetricanalysisintotalskinelectronbeamtherapy
AT simonsenmanuela invivodosimetricanalysisintotalskinelectronbeamtherapy
AT backerdagmar invivodosimetricanalysisintotalskinelectronbeamtherapy
AT haverkampuwe invivodosimetricanalysisintotalskinelectronbeamtherapy
AT eichhanstheodor invivodosimetricanalysisintotalskinelectronbeamtherapy